Lam S K
Dept. of Medicine, University of Hong Kong, Queen Mary Hospital.
Scand J Gastroenterol Suppl. 1990;173:6-16. doi: 10.3109/00365529009091918.
It is unknown why ulcers in general heal. Some clues are worth considering. What is known is (i) that ulcer healing occurs spontaneously, (ii) that ulcers heal more quickly in the duodenum than in the stomach, (iii) that mucosal blood flow at ulcer edge improves with healing, and (iv) that healing can be speeded up by (a) not smoking, (b) removing acid from the stomach, and (c) using non-antisecretory mucosal protective agents such as sucralfate and colloidal bismuth. The difference in healing rates between duodenal and gastric ulcers may be related to ulcer size, duodenal alkalinity due to the secretion of the Brunner's glands, and other uninvestigated factors such as epidermal growth factor and mucosal blood flow. The difference between smokers and non-smokers may be related to inhibition of prostaglandin synthesis and impairment of mucosal blood flow due to smoking and to higher acid secretion in smokers. The success with antisecretory agents indicates that acid inhibits the healing process. The success of sucralfate and bismuth indicates that cytoprotective mechanisms play a role in ulcer healing. The literature also shows that ulcer healing is less affected by smoking in patients treated with sucralfate than in those treated with antisecretory agents, suggesting that cytoprotective mechanisms play a more important part than acid inhibition in counteracting the adverse effects of smoking on healing. Furthermore, ulcer relapse occurs sooner in patients treated with antisecretory agents than in those treated with sucralfate or bismuth, suggesting that withdrawal of antisecretory agents speeds up relapse and/or that cytoprotective mechanisms are associated with longer-lasting remission. It is concluded that sucralfate healing involves cytoprotective mechanisms and that these cannot be ignored in the planning of any anti-ulcer therapy. Despite the understanding of the various site-protective and cytoprotective mechanisms, as discussed in the previous article, it is not clear why ulcers heal with sucralfate. In fact, there is no clear answer to the fundamental question as to why ulcers in general heal with the known therapeutic agents, including H2-receptor antagonists, antacids, proton pump inhibitors, anticholinergics, site-protective agents, and cytoprotective agents. This review examines this question, using sucralfate as a model.
目前尚不清楚溃疡总体上为何会愈合。有一些线索值得考虑。已知的是:(i)溃疡愈合是自发发生的;(ii)十二指肠溃疡比胃溃疡愈合得更快;(iii)溃疡边缘的黏膜血流量会随着愈合而改善;(iv)通过以下方式可以加速愈合:(a)不吸烟;(b)减少胃内的酸;(c)使用非抗分泌性黏膜保护剂,如硫糖铝和胶体铋。十二指肠溃疡和胃溃疡愈合速度的差异可能与溃疡大小、十二指肠腺分泌导致的十二指肠碱性以及其他未研究的因素有关,如表皮生长因子和黏膜血流量。吸烟者和非吸烟者之间的差异可能与吸烟抑制前列腺素合成、损害黏膜血流量以及吸烟者胃酸分泌较高有关。使用抗分泌剂取得的成功表明酸会抑制愈合过程。硫糖铝和铋的成功表明细胞保护机制在溃疡愈合中起作用。文献还表明,与使用抗分泌剂治疗的患者相比,使用硫糖铝治疗的患者的溃疡愈合受吸烟的影响较小,这表明在抵消吸烟对愈合的不利影响方面,细胞保护机制比酸抑制发挥着更重要的作用。此外,使用抗分泌剂治疗的患者比使用硫糖铝或铋治疗的患者溃疡复发更早,这表明停用抗分泌剂会加速复发和/或细胞保护机制与更持久的缓解相关。得出的结论是,硫糖铝促进愈合涉及细胞保护机制,在任何抗溃疡治疗的规划中都不能忽视这些机制。尽管如前一篇文章所讨论的,对各种局部保护和细胞保护机制有了一定的了解,但尚不清楚为什么溃疡会用硫糖铝愈合。事实上,对于为什么一般溃疡会用包括H2受体拮抗剂、抗酸剂、质子泵抑制剂、抗胆碱能药物、局部保护剂和细胞保护剂在内的已知治疗药物愈合这个基本问题,并没有明确的答案。本综述以硫糖铝为模型来探讨这个问题。